Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 2/20 | 0.33 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.32 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | PPARG | P37231 | 1/20 | 0.30 |
| ▸ | PPARD | Q03181 | 1/20 | 0.30 |
| ▸ | PPARA | Q07869 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6735343 | 0.79 | KCNK3 (0.37) | KCNK3KCNK9CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL6737194 | 0.75 | KCNK3 (0.39) | KCNK3KCNK9PPARGPPARDPPARA | |
| SCHEMBL6839841 | 0.74 | GAA (0.35) | KCNK3KCNK9CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL6195926 | 0.74 | GAA (0.33) | KCNK3KCNK9CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL21632117 | 0.73 | FFAR1 (0.41) | KCNK3KCNK9 | |
| SCHEMBL1095410 | 0.73 | KCNK3 (0.39) | KCNK3KCNK9PPARGPPARDPPARA | |
| SCHEMBL6195588 | 0.73 | KCNK3 (0.32) | KCNK3KCNK9SLC6A2SLC6A4PPARG | |
| SCHEMBL21631974 | 0.72 | FFAR1 (0.45) | KCNK3KCNK9PPARGPPARDPPARA | |
| SCHEMBL21656299 | 0.71 | KCNK3 (0.37) | KCNK3KCNK9PPARGPPARDPPARA | |
| SCHEMBL21708650 | 0.69 | KCNK3 (0.36) | KCNK3KCNK9PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040072839-A1 | 1-Phenylalkylpiperazines | RECORDATI S.A. (CH) | 2004-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072839-A1 | 1-Phenylalkylpiperazines | HTR5A, HTR1A, HTR1D | AR 284/4885KCNK3 1292/4885KCNK9 2812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.